ITGAX and neoplasm: Similarly, ZD55-IL-24 treatment alone led to a small but statistically significant increase of DCs in spleens as well, despite there was no difference in MHC II+CD11c− APCs (Fig. 6e, f), further indicating that ZD55-IL-24 but not PD-1 blockade was able to improve tumor immune recognition in spleens.